Modern science has brought to light an innovative neurotechnology developed by ICN2 and numerous partnerships that consist of a graphene-based component which holds tremendous potential to revolutionise the field of neuroscience and its therapeutic applications. The study introducing this groundbreaking neurotechnology was recently published in the esteemed scientific journal, Nature Nanotechnology.
Constructed through an intensive research process under the umbrella of the European Graphene Flagship project, a fresh classification of implantable neurotechnology — EGNITE, was created. Hierarchically engineered by ICN2 in partnership with the University of Manchester and constructed with nanoporous graphene, this technology signifies an emergence of superior quality, adeptness and flexibility in neuroelectronic implants.
EGNITE’s design is intriguing as it conspicuously displays the blend of vast knowledge and practical experience of its inventors in the overall creation and medical manifestation of carbon nanomaterials. A unique feature of this graphene-based technology is its compatibility with conventional semiconductor industry manufacturing processes, signifying an adoption of standardised methods while incorporating modern advancements.
Furthermore, a key attribute presented by this technology is its high-resolution neural interfaces and precise nerve modulation capability. Validated by various preclinical studies, EGNITE provides high-fidelity signal recording with exceptional clarity and precision. Moreover, its efficient nerve stimulation adds enormous therapeutic benefit. These unique features indeed revolutionise the neurotechnology scene and overcome past hurdles in the field by promising a significant leap in technological advancements and its therapeutic uses.
The inception of EGNITE technology further highlights an exemplary international collaboration between some of the world’s top scientific and educational institutions like Institut de Microelectrònica de Barcelona, National Graphene Institute in Manchester, Grenoble Institut des Neurosciences, and the University of Barcelona. The profound input of each institute has enhanced the technological advancement towards cutting-edge materials research in neurotechnology.
This pinnacle of innovative and integrated neurotechnology is now officially patented and licensed to INBRAIN Neuroelectronics, a spin-off located in the beautiful city of Barcelona. Spearheaded by CEO Carolina Aguilar, the company has taken the responsibility for ushering this technology into the clinical applications phase. With state-of-the-art facilities earmarked for semiconductor technologies based on emerging materials, Catalonia is set to witness an exceptional acceleration in the field of clinical neuroscience.
In conclusion, the advent of this avant-garde graphene-based neurotechnology, with the potential for largescale production using existing semiconductor production techniques, generates a promising possibility for transformational impact. ICN2, along with its partners, is steadfast in its continued efforts to nurture the technology further, with an ultimate aim to translate the technology into a productive, therapeutic neurotechnology solution. This breakthrough provides a new ray of hope in neuroscience, foreseeing an exciting journey of biomedical innovation in the years to come.
